INSIGHTS ON CLINICAL TRIAL PARTNERING
-
What Sponsors Must Know To Safeguard Ocular Endpoints
Explore the necessity of incorporating imaging methodologies early in the trial design to improve data quality and overall trial efficiency.
-
Considerations For Drug-Device Combination Products In Rare Diseases
The development process for these products is complex, requiring careful consideration of regulatory requirements, technical feasibility, clinical efficacy, and patient-centered design.
-
The Tax Reporting Threshold Just Went from $600 to $2K — What to Know
Explore the implications of the newly enacted "One Big Beautiful Bill" and how it will alleviate the administrative burdens faced by clinical research stakeholders and benefit low-income patients.
-
Decentralized Trials Still Need Connected Support
Decentralized and hybrid trials reduce travel burdens but add coordination challenges. Strong support improves communication, engagement, and smooth trial execution from enrollment to completion.
-
Advantages Of Sourcing Biosimilars Vs. Branded Biologics In Clinical Trials3/12/2026
Evaluate biosimilar alternatives during clinical trial planning to reduce comparator drug costs and improve overall study efficiency without compromising trial integrity.
-
Why Use Scorecards To Make Vendor Selection Decisions10/21/2025
Scorecards enable structured, unbiased vendor selection by transforming complex clinical trial decisions into transparent, data-driven evaluations — ensuring operational excellence and regulatory compliance.
-
What Sponsors Get Wrong When Selecting A CRO3/9/2026
Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.
-
What Sites Really Want: Insights From The 2024 Site Landscape Survey7/15/2025
Take a closer look at the 2024 SCRS Site Landscape Survey—and what sites say they need most. Less friction. More follow-through. And partners who actually lighten the load.
-
The Importance Of Cognitive And Pharmacodynamic Testing During FIH Trials5/9/2025
Learn how to identify which cognitive and pharmacodynamic tests are required for novel CNS-active drugs and best practices on conducting them during First-In-Human (FIH) trials.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
ClinAI helps you centralize RFPs, budgets, and vendor data—so you can select the right partners, manage change orders, and keep your studies on track.
-
Flexible, scalable capabilities for autoinjectors, pens, and prefilled syringes — ranging from manual to fully automated — streamlining and simplifying your biologic drug development supply chain.
-
Our priority is guiding promising therapies to proof-of-concept with precision and urgency, because every day saved in development matters profoundly to patients living with cancer.
-
Sikich SuiteSuccess for CROs can completely transform the CRO business with resource management and finance. Explore some ways SuiteSuccess for CROs helps you control and build CRO business growth.
-
Learn more about the Global ESG Program and how the continued development of sustainability initiatives contributes to positive impact on the environment and the communities in which we operate.